Acadia claims Alzheimer's success

The company is pushing ahead into Phase 3 trials, despite skepticism. 

By Suzanne Elvidge • Dec. 21, 2016

Prescribed Reading: Bad behavior abounds in biopharma

Charges have come down in a generics price-fixing investigation, while Ophthotech reports deep staff cutbacks and the FDA cautions on misleading advertising.

By Lisa LaMotta • Dec. 16, 2016

Explore the Trendline➔

Neuroscience drug development

Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.

By BioPharma Dive staff

RespireRx nets mixed results in Phase 2

The New Jersey-based company is developing a treatment for opioid-induced respiratory depression and sleep apnea. 

By Suzanne Elvidge • Dec. 16, 2016

Centrexion osteoarthritis drug hits its mark in Phase 2

The announcement closes out an active year for the company, which has been working to establish itself in the pain medication space.

By Jacob Bell • Dec. 13, 2016

Achaogen's stocks fly high on antibiotic clinical success

Shares in the biopharma spiked after news its drug plazomicin beat out the last-resort antibiotic colistin in treating complex infections.

By Suzanne Elvidge • Dec. 13, 2016

Armed with IPO cash, CRISPR biotechs grow gene-editing tech

Even as a high-stakes patent battle steals headlines, the three CRISPR biotechs which IPO'd this year are busy building momentum. 

By Ned Pagliarulo • Dec. 12, 2016

Novartis, Ophthotech combo therapy fails in Phase 3

The clinical results effectively sideline a potential competitor to Regeneron's blockbuster drug Eylea.

By Jacob Bell • Dec. 12, 2016

Prescribed Reading: Cures for pharma funding

Cures provides funding for pharma research, while AstraZeneca and Lilly continue their pursuit of an Azheimer's treatment, and CAR-Ts wow at ASH. 

By Lisa LaMotta • Dec. 9, 2016

Valeant upbeat on Phase 3 success for psoriasis drug

Yet a crushing debt burden and floundering efforts to sell off assets has limited investor confidence in the company's new look. 

By Suzanne Elvidge • Dec. 9, 2016

Biogen boosted by early Alzheimer's data

In the wake of Eli Lilly's high-profile solanezumab miss, attention has shifted to Biogen's aducanumab as the most promising Alzheimer's candidate. 

By Ned Pagliarulo • Dec. 9, 2016

Horizon tanks on Phase 3 failure

The specialty pharma is pulling out of its Friedreich's ataxia program after the drug missed its primary and secondary endpoints in the study. 

By Lisa LaMotta • Dec. 8, 2016

AbbVie breast cancer drug falls short in Phase 2

A larger, pivotal Phase 3 study of the PARP inhibitor will be the real test for the drug's potential in BRCA-mutated breast cancer. 

By Ned Pagliarulo • Dec. 7, 2016

ASH: I/O drugs pushing into blood cancers

Merck & BMS trumpeted CHL results for Keytruda and Opdivo/Adcetris as part of their aim to move beyond solid tumors.

By Suzanne Elvidge • Dec. 7, 2016

ADCs: A booming field for new cancer-fighting therapies

Tens of thousands of patients already use the two marketed antibody-drug conjugate products, and the pipeline is brimming with second-generation offerings. 

By Judy Packer-Tursman • Dec. 7, 2016

5 biggest Alzheimer's trial setbacks

In the wake of the latest Alzheimer's drug failure, BioPharma Dive revisited a therapeutic field littered with failures. 

By Lisa LaMotta • Dec. 7, 2016

AstraZeneca touts Tagrisso's edge in lung cancer

Results showed the drug extended progression-free survival by a median of 6 months compared to standard chemotherapy.  

By Jacob Bell • Dec. 6, 2016

Roche's Gazvya edges Rituxan in Phase 3

Yet the successor drug only slightly improved overall survival rates at 3 years, which coupled with riskier safety profile, could lessen its competitive advantage. 

By Suzanne Elvidge • Dec. 6, 2016

Karyopharm storms into ASH with updated Phase 2b data

Selinexor data reinforces safety and efficacy in heavily-pretreated multiple myeloma

By Suzanne Elvidge • Dec. 6, 2016

Juno turns to JCAR017 amid Rocket setback

Positive results presented at ASH Monday likely mean JCAR017 will be the focus moving forward, as Juno mulls axing JCAR015. 

By Ned Pagliarulo • Dec. 5, 2016

Spark teams up with Selecta on gene therapies

The gene therapy biotech will use Selecta's technology platform to bolster the efficacy of its hemophilia therapies. 

By Lisa LaMotta • Dec. 5, 2016

Alnylam scores ASH win in hemophilia

Encouraging results from an early study showed Alnylam's experimental drug fitusiran helps control bleeding even among hard-to-treat patients. 

By Ned Pagliarulo • Dec. 5, 2016

ASH: Spark highlights promise of gene therapy

Early clinical trial results offer hope for patients with the debilitating bleeding disorder. 

By Lisa LaMotta • Dec. 5, 2016

Novartis forges ahead with lead CAR-T

The Swiss pharma plans to file for approval of CTL019 in early 2017 after presenting encouraging data at ASH over the weekend. 

By Ned Pagliarulo • Dec. 5, 2016

Shire's Vonvendi controls surgical bleeding

Acquired through the Baxalta acquisition, Vonvendi hit its primary endpoint and data will contribute to a supplementary NDA.

By Suzanne Elvidge • Dec. 5, 2016

Prescribed Reading: Spotlight on CAR-T, Cures

AstraZeneca inks small deal that will fit into its new focus; the upcoming ASH meeting will highlight the progress in CAR-T; and the Cures Act gets support from the industry. 

By Lisa LaMotta • Dec. 2, 2016